Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study

BACKGROUND: Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo patients and patients in early therapy escalation. OBJECTIVE: To investigate the safety and efficacy of off-label t...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mult Scler J Exp Transl Clin
Egile Nagusiak: Torgauten, Hilde Marie, Myhr, Kjell-Morten, Wergeland, Stig, Bø, Lars, Aarseth, Jan H, Torkildsen, Øivind
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2021
Gaiak:
Original Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970692/
https://ncbi.nlm.nih.gov/pubmed/33796328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217320973049
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak